Copyright © 2002 by the European Society of Cardiology.
Editorials
r-Hirudin for percutaneous coronary interventionstime to reconsider?
University Hospital, Bern, Switzerland
References
- Chew DP, Bhatt DL, Lincoff AM. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001;103:961966
[Abstract/Free Full Text] - Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation. 2001;103:14791484
[Abstract/Free Full Text] - Meyer BJ, Badimon JJ, Chesebro JH. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin. Circulation. 1998;97:681685
[Abstract/Free Full Text] - Serruys PW, Herrman JP, Simon R. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med. 1995;333:757763
[Abstract/Free Full Text] - Bittl JA, Strony J, Brinker JA. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med. 1995;333:764769
[Abstract/Free Full Text] - Roe MT, Granger CB, M OE. Hirudin significantly reduces ischemic events following coronary intervention for acute coronary syndromes. J Am Coll Cardiol. 2000;35:39A
- Lancet. 1999;353:429438[CrossRef][ISI][Medline]
- Mehta SR, Eikelboom JW, Rupprecht H-J. Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention. Eur Heart J. 2002;23:117123
[Abstract/Free Full Text] - Lancet. 1997;349:14291435[CrossRef][ISI][Medline]
- N Engl J Med. 1997;336:16891696
[Abstract/Free Full Text] - Moshfegh K, Redondo M, Julmy F. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol. 2000;36:699705
[Abstract/Free Full Text] - Topol EJ. Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET). Am J Cardiol. 1998;82:63P68P[CrossRef][ISI][Medline]
- Lancet. 2001;358:527533[CrossRef][ISI][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||